K073091

# FEB 2 9 2008

# 510(k) SUMMARY

# VIDAS® NT-proBNP Assay

A. Submitter Information Submitter's Name: Address:

bioMérieux, Inc.   
595 Anglum Road   
Hazelwood, MO 63042   
Nikita S. Mapp   
314-731-7474   
314-731-8689   
October 2007 (revised February 2008)

Contact Person: Phone Number: Fax Number: Date of Preparation:

B. Device Name Trade Name:

VIDAS® NT-proBNP

Common Name:

Endotoxin Assay

Classification Name:

21 CFR 862.1117 Product Code NBC B-type natriuretic peptide test system

C. Predicate Device Name Trade Name:

Elecsys proBNP Assay

# Device Description

The VIDAS® NT-proBNP assay is an automated quantitative test for use on the VIDAS instruments for the determination of N terminal fragment of B-type natriuretic peptide in human serum or plasma (lithium heparin) using the ELFA (Enzyme-Linked Fluorescent Assay) technique. The VIDAS NT-proBNP test is used as an aid in the diagnosis of suspected congestive heart failure.

The assay principle combines a one-step immunoassay sandwich method with a final fluorescent detection (ELFA). The Solid Phase Receptacle (SPR), a pipette tip-like device, serves as the solid phase as well as the pipetting device for the assay. The assay reagents are ready-to-use and pre-dispensed in the sealed reagent strips (STRs). The individual kit components are described in detail in the $5 1 0 ( k )$ and in the package insert.

All of the assay steps are performed automatically by the VIDAS instrument. The sample is transferred into the well containing anti-NT-proBNP antibody (conjugate) labeled with alkaline phosphatase. The sample/conjugate mixture is cycled in and out of the SPR several times. This operation enables the antigen to bind with the immunoglobulins fixed to the interior wall of the SPR and the conjugate to form a sandwich. Unbound compounds are eliminated during washing steps.

Two detection steps are performed successively. During each step, the substrate (4-Methylumbelliferyl phosphate) is cycled in and out of the SPR. The conjugate enzyme catalyzes the hydrolysis of this substrate into a fluorescent product (4-Methyl-umbelliferone) the fluorescence of which is measured at 450 nm. The intensity of the fluorescence is proportional to the concentration of antigen present in the sample.

At the end of the assay, results are automatically calculated by the ViDAS instrument in relation to two calibration curves corresponding to the two detection steps stored in memory, and then printed out.

# E. Intended Use

The VIDAS® NT-proBNP assay is an automated quantitative test for use on the VIDAS instruments for the determination of N terminal fragment of B-type natriuretic peptide in human serum or plasma (lithium heparin) using the ELFA (Enzyme-Linked Fluorescent Assay) technique. The VIDAS NT-proBNP test is used as an aid in the diagnosis of suspected congestive heart failure.

# F. Technological Characteristics Summary

A general comparison of the similarities and differences of the assays is presented in the table below.

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device[VIDAS NT-proBNP]</td><td rowspan=1 colspan=1>Predicate[Elecsys proBNP]</td></tr><tr><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=3>General Comparison</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Quantitative determination of N terminalfragment of B-type natriuretic peptide inhuman serum or plasma (lithium heparin).The VIDAS NT-proBNP test is used as anaid in the diagnosis of suspected congestiveheart failure.</td><td rowspan=1 colspan=1>Same as initial claim [K022516].Roche obtained additional claims viaother 510(k)s, &quot;risk stratification&quot; and&quot;risk assessment &quot; which bioMerieux isnot pursuing at this time.</td></tr><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Human serum or plasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Measures NT-proBNP</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Anti-NT-proBNP   antibody   (polyclonalsheep)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay Principle</td><td rowspan=1 colspan=1>Immunoassay based on sandwich principle</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Automated</td><td rowspan=1 colspan=1>Automated assay</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay Technique</td><td rowspan=1 colspan=1>Enzyme-Linked Fluorescent Assay (ELFA)</td><td rowspan=1 colspan=1>Electrochemiluminescent assay</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>200 μl</td><td rowspan=1 colspan=1>20 μl</td></tr><tr><td rowspan=1 colspan=1>Assay Time</td><td rowspan=1 colspan=1>~20 minutes</td><td rowspan=1 colspan=1>18 minutes</td></tr><tr><td rowspan=1 colspan=1>Traceability/Standardization</td><td rowspan=1 colspan=1>Traceable to proBNP Roche</td><td rowspan=1 colspan=1>Reference standardpurifiedsynthetic NTG-proBNP (1-76) inhuman serum matrix</td></tr><tr><td rowspan=1 colspan=1>Measurement range</td><td rowspan=1 colspan=1>20-25,000 pg/mL</td><td rowspan=1 colspan=1>5-35,000 pg/mL</td></tr></table>

G. Performance Data

A summary of the non-clinical and clinical test results is presented in the table below.   

<table><tr><td colspan="1" rowspan="1">Test</td><td colspan="1" rowspan="1">Device[VIDAS NT-proBNP]</td><td colspan="1" rowspan="1">Predicate[Elecsys proBNP]</td></tr><tr><td></td><td></td><td></td></tr><tr><td colspan="3" rowspan="1">Non-clinical (Analytical) Comparison</td></tr><tr><td colspan="1" rowspan="1">Matrix Comparison</td><td colspan="1" rowspan="1">Serum similar to PlasmaFor patient follow-up, assays must be performedon the same type of sample tube.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Precision</td><td colspan="1" rowspan="1">5 samples tested in duplicate in 40 differentruns (2 runs per day)repeatability (intra-run): 1.5 - 2.8 %CVinter-site: 3.4 -5.1 %CVinter-lot: 3.5 - 8.4 %CV</td><td colspan="1" rowspan="1">4 samples tested in 6 times daily for10 daystotal precision: 2.2 - 3.2%CVwithin run precision: 1.8 - 2.7%CV</td></tr><tr><td colspan="1" rowspan="1">Detection Limits</td><td colspan="1" rowspan="1">&lt; 20 pg/mL(LoB = 3.4 pg/mL, LoD = 6.7 pg/mL, LoQ =13.9 pg/mL)</td><td colspan="1" rowspan="1">5 pg/ml</td></tr><tr><td colspan="1" rowspan="1">Interfering SubstancesBilirubinHemoglobinTriglyceridesAlbuminHuman IgGHuman IgMRheumatoid Factors</td><td colspan="1" rowspan="1">No significant interference30 mg/dl (510 μmol/L)485 mg/di (300 μmol/L)30 g/l100 g/L17 g/L6 g/L1500 1U/mL</td><td colspan="1" rowspan="1">No significant interference35 mg/dl1.4 g/dl4000 mg/dlNot testedNot testedNot tested1500 IU/mL</td></tr><tr><td colspan="1" rowspan="1">Analytical SpecificityAdrenomedullinAldosteroneAngiotensin IAngiotensin IIAngiotensin IIIANP Arg-VasopressinBNP32CNP22EndothelinNT-proANP1-30NT-proANP31-67NT-proANP79-98ReninUrodilatin</td><td colspan="1" rowspan="1">&lt;0.1%&lt;0.1%&lt;0.1%&lt;0.1%&lt;0.1%&lt;0.1%&lt;0.1%&lt;0.1%&lt;0.1%&lt;0.1%&lt;0.1%&lt;0.1%&lt;0.1%&lt;0.1%&lt;0.1%</td><td colspan="1" rowspan="1">&lt;0.001%&lt;0.001%&lt;0.001%&lt;0.001%&lt;0.001%&lt;0.001%&lt;0.001%&lt;0.001%&lt;0.001%&lt;0.001%&lt;0.001%&lt;0.001%&lt;0.001%&lt;0.001%&lt;0.001%</td></tr><tr><td colspan="1" rowspan="1">Drug Interference</td><td colspan="1" rowspan="1">No interference was observed on 39frequently administered drugs tested in vitro</td><td colspan="1" rowspan="1">No interference found on commonlyused pharmaceuticals</td></tr><tr><td colspan="1" rowspan="1">Hook Effect</td><td colspan="1" rowspan="1">No hook effect found up to concentrationsof 500,000 pg/mL</td><td colspan="1" rowspan="1">No hook effectfoundup toconcentrations of 300,000 pg/mL</td></tr><tr><td colspan="3" rowspan="1">Clinical Comparison</td></tr><tr><td colspan="1" rowspan="1">Cut-off</td><td colspan="1" rowspan="1">125 pg/mL for patients &lt;75 years old450 pg/mL for patients ≥ 75 years old</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">Clinical Sensitivity/Specificity Studies</td></tr><tr><td colspan="3" rowspan="1">Reference Group (without CHF)</td></tr><tr><td colspan="1" rowspan="1">Number of patients</td><td colspan="1" rowspan="1">411 patients</td><td colspan="1" rowspan="1">1411 patients</td></tr><tr><td colspan="1" rowspan="1">Study Site(s)</td><td colspan="1" rowspan="1">US and Europe</td><td colspan="1" rowspan="1">unknown</td></tr><tr><td colspan="3" rowspan="1">Results</td><td colspan="2" rowspan="1">% &lt; cut-off (males and females)&lt;45 yrs: 92.4%45-54 yrs: 90.3%55-64 yrs: 95.4%65-74 yrs: 89.5%&lt;75 yrs: 92.2%≥75+ yrs: 95.7%</td><td colspan="2" rowspan="1">% &lt; 125 pg/mL (all)&lt;45 yrs: 95.7%45-54 yrs: 93.3%55-64 yrs: 83.3%65-74 yrs: 69.8%&lt;75 yrs: 82.4%% &lt; 450 pg/mL (all)75+ yrs: 88.9%</td></tr><tr><td colspan="3" rowspan="1"></td><td colspan="2" rowspan="1">Disease Group (with CHF)</td><td colspan="2" rowspan="1"></td></tr><tr><td colspan="3" rowspan="1">Number of patients</td><td colspan="2" rowspan="1">407 patients</td><td colspan="2" rowspan="1">721 patients</td></tr><tr><td colspan="3" rowspan="1">Study Site(s)</td><td colspan="2" rowspan="1">US and Europe</td><td colspan="2" rowspan="1">unknown</td></tr><tr><td colspan="3" rowspan="1">Results</td><td colspan="2" rowspan="1">% ≥ cut-off (males and females)&lt;45 yrs: 85.0%45-54 yrs: 85.3%55-64 yrs: 88.1%65-74 yrs: 100.0%&lt;75 yrs: 92.3%≥75+ yrs: 91.5%</td><td colspan="2" rowspan="1">% &lt; 125 pg/mL (all)&lt;45 yrs: 82.8%45-54 yrs: 88.5%55-64 yrs: 89.5%65-74 yrs: 92.2%75+ yrs: unknown&lt;75 yrs: 89.3%% &lt; 450 pg/mL (all)75+ yrs: 84.7%</td></tr><tr><td colspan="7" rowspan="1">Sensitivity and Specificity vs. gender and age</td></tr><tr><td colspan="7" rowspan="4">European Site 1Statistics                 All patients                 &lt;75yrs.                   ≥75 yrs.Sensitivity (%)         94.63 (89.64-97.29)        100 (94.81-100)        89.47 (80.36-94.64)Specificity(%)         97.39 (93.36-99.00)      97.27 (92.14-99.09)       97.67 (87.63-99.6)</td></tr><tr><td colspan="1" rowspan="1">Statistics</td><td colspan="2" rowspan="1">All patients</td><td colspan="2" rowspan="1">&lt;75yrs.</td><td colspan="1" rowspan="1">≥75 yrs.</td></tr><tr><td colspan="1" rowspan="1">Sensitivity (%)</td><td colspan="2" rowspan="1">94.63 (89.64-97.29)</td><td colspan="2" rowspan="1">100 (94.81-100)</td><td colspan="1" rowspan="1">89.47 (80.36-94.64)</td></tr><tr><td colspan="1" rowspan="1">Specificity(%)</td><td colspan="2" rowspan="1">97.39 (93.36-99.00)</td><td colspan="2" rowspan="1">97.27 (92.14-99.09)</td><td colspan="1" rowspan="1">97.67 (87.63-99.6)</td></tr><tr><td></td><td colspan="6" rowspan="1">European Site 2</td><td colspan="1" rowspan="5"></td></tr><tr><td></td><td colspan="1" rowspan="1">Statistics</td><td colspan="2" rowspan="1">All patients</td><td colspan="2" rowspan="1">&lt;75yrs.</td><td colspan="1" rowspan="1">≥.75 yrs.</td></tr><tr><td></td><td colspan="1" rowspan="1">Sensitivity(%)</td><td colspan="2" rowspan="1">94.96 (89.84-97.57)</td><td colspan="2" rowspan="1">94.23 (84.08-98.06)</td><td colspan="1" rowspan="1">95.4 (88.58-98.23)</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Specificity (%)</td><td colspan="2" rowspan="1">96.69 (92.37-98.6)</td><td colspan="2" rowspan="1">96.36 (90.87-98.6)</td><td colspan="1" rowspan="1">97.56 (87.09-99.58)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="6" rowspan="1">US Site</td><td colspan="1" rowspan="5">|</td></tr><tr><td></td><td colspan="1" rowspan="1">Statistics</td><td colspan="2" rowspan="1">All patients</td><td colspan="2" rowspan="1">&lt; 75 yrs.</td><td colspan="1" rowspan="1">275 yrs.</td></tr><tr><td></td><td colspan="1" rowspan="1">Sensitivity(%)</td><td colspan="2" rowspan="1">84.87 (77.18-90.3)</td><td colspan="2" rowspan="1">82.86 (72.14-90.02)</td><td colspan="1" rowspan="1">87.76 (75.46-94.35)</td></tr><tr><td></td><td colspan="1" rowspan="1">Specificity(%)</td><td colspan="2" rowspan="1">81.31 (72.69-87.67)</td><td colspan="2" rowspan="1">81.82 (72.88-88.28)</td><td colspan="1" rowspan="1">75 (40.31-93.02)</td></tr><tr><td colspan="7" rowspan="1"></td></tr><tr><td colspan="7" rowspan="4">All Sites CombinedStatistics                 All patients                 &lt; 75 yrs.                   ≥75 yrs.Sensitivity (%)         91.89 (88.76-94.21)      92.31 (87.58-95.33)      91.51 (86.87-94.61)Specificity (%)         92.94 (89.98-95.08)       92.16 (88.6-94.68)       95.65 (89.17-98.33)</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Statistics</td><td colspan="2" rowspan="1">All patients</td><td colspan="2" rowspan="1">&lt; 75 yrs.</td><td colspan="1" rowspan="1">≥75 yrs.</td></tr><tr><td colspan="1" rowspan="1">Sensitivity (%)</td><td colspan="2" rowspan="1">91.89 (88.76-94.21)</td><td colspan="2" rowspan="1">92.31 (87.58-95.33)</td><td colspan="1" rowspan="1">91.51 (86.87-94.61)</td></tr><tr><td colspan="1" rowspan="1">Specificity (%)</td><td colspan="2" rowspan="1">92.94 (89.98-95.08)</td><td colspan="2" rowspan="1">92.16 (88.6-94.68)</td><td colspan="1" rowspan="1">95.65 (89.17-98.33)</td></tr><tr><td colspan="1" rowspan="1">Statistics</td><td colspan="1" rowspan="1">Males</td><td colspan="1" rowspan="1">Males &lt; 75 yrs.</td><td colspan="1" rowspan="1">Males ≥ 75 yrs.</td></tr><tr><td colspan="1" rowspan="1">Sensitivity (%)</td><td colspan="1" rowspan="1">92.92 (88.85-95.57)</td><td colspan="1" rowspan="1">94.07 (88.6-97.01)</td><td colspan="1" rowspan="1">91.43 (84.33-95.48)</td></tr><tr><td colspan="1" rowspan="1">Specificity (%)</td><td colspan="1" rowspan="1">95.67 (92.13-97.66)</td><td colspan="1" rowspan="1">95.31 (91.23-97.55)</td><td colspan="1" rowspan="1">97.44 (86.49-99.56)</td></tr><tr><td colspan="4" rowspan="1">Females: All Sites Combined</td></tr><tr><td colspan="1" rowspan="1">Statistics</td><td colspan="1" rowspan="1">Females</td><td colspan="1" rowspan="1">Females &lt; 75 yrs.</td><td colspan="1" rowspan="1">Males ≥ 75 yrs.</td></tr><tr><td colspan="1" rowspan="1">Sensitivity (%)</td><td colspan="1" rowspan="1">90.42 (84.87-94.07)</td><td colspan="1" rowspan="1">88.33 (77.56-94.31)</td><td colspan="1" rowspan="1">91.59 (84.61-95.57)</td></tr><tr><td colspan="1" rowspan="1">Specificity(%)</td><td colspan="1" rowspan="1">89.44 (83.98-93.2)</td><td colspan="1" rowspan="1">87.4 (80.35-92.17)</td><td colspan="1" rowspan="1">94.34 (84.36-98.1)</td></tr></table>

# H. Conclusion The VIDAS® NT-proBNP Assay is substantially equivalent to the Roche Elecsys proBNp Assay.

The 510(k) summary includes only information that is also covered in the body of the 510(k). The summary does not contain any puffery or unsubstantiated labeling claims. The summary does not contain any raw data, i.e., contains only summary data. The summary does not contain any trade secret or confidential commercial information. The summary does not contain any patient identification information.

bioMerieux, Inc   
c/o Ms. Nikita Mapp   
Senior Regulatory Affairs Specialist   
595 Anglum Road   
Hazelwood, MO 63042

# FEB 2 9 2008

Re: k073091 Trade/Device Name: VIDAS NT-proBNP Assay Regulation Number: 21 CFR 862.1117 Regulation Name: B-type natriuretic peptide test system Regulatory Class: Class II Product Code: NBC

Dated: February 04, 2008   
Received: February 05, 2008

Dear Ms. Mapp:

We have reviewed your Section $5 1 0 ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with allthe Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Jean M. Coopes, M.S., D.V.M. Jean M. Cooper, M.S., D.V.M.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and   
Radiological Health

Enclosure

# Indication for Use

510k)Num

Device Name: VIDAS NT-proBNP Assay

Indication For Use: ${ \mathsf { V I D A S } } ^ { \otimes }$ NT-proBNP assay is an automated quantitative test for use on the VIDAS instruments for the determination of N terminal fragment of B-type natriuretic peptide in human serum or plasma (lithium heparin) using the ELFA (Enzyme-Linked Fluorescent Assay) technique. The VIDAS NT-proBNP test is used as an aid in the diagnosis of suspected congestive heart failure.

# Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/89acc4bf38969833a3e52a4efde98d5a9b5b2da281663226349be1014acdba5e.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety